The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey

Item Type:	Article
Title:	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey
Creators Name:	Bocchetta, M. and Galluzzi, S. and Kehoe, P.G. and Aguera, E. and Bernabei, R. and Bullock, R. and Ceccaldi, M. and Dartigues, J.F. and de Mendonca, A. and Didic, M. and Eriksdotter, M. and Felician, O. and Froelich, L. and Gertz, H.J. and Hallikainen, M. and Hasselbalch, S.G. and Hausner, L. and Heuser, I. and Jessen, F. and Jones, R.W. and Kurz, A. and Lawlor, B. and Lleo, A. and Martinez-Lage, P. and Mecocci, P. and Mehrabian, S. and Monsch, A. and Nobili, F. and Nordberg, A. and Rikkert, M.O. and Orgogozo, J.M. and Pasquier, F. and Peters, O. and Salmon, E. and Sanchez-Castellano, C. and Santana, I. and Sarazin, M. and Traykov, L. and Tsolaki, M. and Visser, P.J. and Wallin, A.K. and Wilcock, G. and Wilkinson, D. and Wolf, H. and Yener, G. and Zekry, D. and Frisoni, G.B.
Abstract:	We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Abeta42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.
Keywords:	Biomarkers, Alzheimer's Disease, Mild Cognitive Impairment, Diagnosis
Source:	Alzheimer's & Dementia
ISSN:	1552-5260
Publisher:	Elsevier
Volume:	11
Number:	2
Page Range:	195-206
Date:	February 2015
Official Publication:	https://doi.org/10.1016/j.jalz.2014.06.006
PubMed:	View item in PubMed

Repository Staff Only: item control page